

<b>DATE:</b>	22 October 2025
<b>TO:</b>	All Hematologists and Pathologists in Alberta
<b>FROM:</b>	Molecular Pathology Program, Alberta Precision Laboratories
<b>RE:</b>	<b>JAK2 V617F Test Delays</b>

---

## PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

---

### Key Message

- Provincial JAK2 V617F testing will experience delayed turnaround times (TAT) over the next several weeks due to a reagent shortage from the vendor. Requests will be prioritized based on estimated pre-test probability of JAK2 V617F. Kits are expected to be received in mid-November at which time regular testing will resume.

### Background

- JAK2 V617F targeted testing is performed in Calgary and Edmonton utilizing the same method with a 2 week target TAT.
- The Qiagen Ipsogen kits required to run JAK2 V617F testing at both sites are on backorder until mid-November. The remaining kit supply on-hand in Alberta is not sufficient to maintain full testing volumes at target TATs until kits are expected.
- No suitable external lab for sendout testing was identified.
- The remaining kits on hand in APL MolPath will be rationed to test high priority samples including:
  - Cases where both JAK2 and reflexive myeloid NGS have been requested, which have a higher pre-test probability of JAK2 V617F.
  - Other cases with a higher estimated pre-test probability based on chart review.

### How this will impact you

- Over the next several weeks, many JAK2 V617F orders will experience delayed TATs.

### Action Required

- Hematologists and Pathologists:** Be aware that JAK2 V617F results will experience delayed TATs over the next several weeks. If clinically urgent targeted JAK2 V617F testing is required for a specific patient during this time, please communicate directly with the molecular pathology laboratory to request that it be prioritized.

**Effective**      **October 22, 2025**

### Questions/Concerns

- Dr. Erik Nohr, Scientific Lead, Molecular Pathology South [erik.nohr@albertaprecisionlabs.ca](mailto:erik.nohr@albertaprecisionlabs.ca)
- Dr. Cheryl Mather, Medical Lead, Molecular Pathology North [cheryl.mather@albertaprecisionlabs.ca](mailto:cheryl.mather@albertaprecisionlabs.ca)
- Dr. Adrian Box, Medical/Scientific Director, Molecular Pathology Program  
[adrian.box@albertaprecisionlabs.ca](mailto:adrian.box@albertaprecisionlabs.ca)

### Approved by

- Dr. Erik Nohr, Acting Provincial Medical/Scientific Director, Molecular Pathology Program
- Camille Jackson, Manager - Genetics & Genomics/Molecular Pathology -South
- Dr. Carolyn O'Hara, Chief Medical Laboratory Officer (Interim), Alberta Precision Laboratories